Nasdaq: BRVE
Braveheart Bio insiders
The officers, directors and 10% owners of Braveheart Bio, Inc. who hold the most stock, valued at the live BRVE price.
$19.27
BRVE today +$740K (+3.99%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 8
- Their BRVE stock
- $754M
- Market value
- $1.58B
- Held by ranked insiders
- 47.7%
Insiders by value of BRVE holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% owner | 21,826,024 | $421M | 26.6% | Corporate |
| 2 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% owner | 7,420,091 | $143M | 9.04% | Corporate |
| 3 | Travis Murdoch | CEO and President | 7,306,241 | $141M | 8.90% | 1160th |
| 4 | David I. Malek | Director | 773,571 | $14.9M | 0.94% | 6476th |
| 5 | Christopher Viehbacher | Director | 759,857 | $14.6M | 0.93% | 4810th |
| 6 | James Paul Rickey | Chief Financial Officer | 612,251 | $11.8M | 0.75% | 7757th |
| 7 | Michele A. Anderson | Chief Development Officer | 332,161 | $6.4M | 0.40% | 12189th |
| 8 | Jason Coloma V. | Director | 93,607 | $1.8M | 0.11% | 5362nd |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Braveheart Bio; see each profile for the filing.